Treatment with drugs orally is 52% more effective in multiple sclerosis

The Gilenya (fingolimode), Novartis lab, is the first oral treatment for multiple sclerosis (MS) and is bringing satisfactory results for patients with the disease, to facilitate treatment adherence in many ways, unlike options available, such as injectables. Treatment was awarded the Prix Galien Italian 2012, in the category innovator of the year.

When properly follow treatment, be administered orally, MS patient has immediate improvement in quality of life, reduce surge noting that manifests itself in several ways physical and psychological for achieving the central nervous system.

In studies, the drug has also demonstrated effectiveness in reducing upper 52% of outbreaks caused by the disease, compared to one of the most widely used treatments.

Since its global launch, over 49,000 patients have been treated with fingolimode. The drug was approved in Europe in 2011 and is available in the Brazilian market and in several other countries such as United States, Canada, Russia, Australia, Argentina, Chile and Mexico.

Multiple sclerosis is a demyelinating disease of neurological and inflammatory character most common neurodegenerative central nervous system, affecting about 2.5 million people worldwide, according to WHO data. Cause significant and progressive disability in most affected individuals, and the most common cause of acquired neurological disability in young adults.

• Tweet